Replicel

[PinotQ]

In projecting the potential stock price of Replicel by calculating how much revenue they will produce, the full NBT report referred to last week says that:

"Revenue is generated in two streams:
1. Assumed annual license fee of $20,000 to each RepliCel licensed clinician performing the procedure.
2. Per-patient fee of $15,000 for the replication of each patient’s cells."

This doesn't take into account that the doctor performing the procedure would also charge a fee. It's worth noting that the report also says that:


"It is estimated that the number of licensed practitioners performing the procedure will double each year beginning with six in the first year. By the year 2018, it is estimated that there will be 48 practitioners performing the procedure equating to over $580 million in patient fees alone and approximately $1 million per year in licensing fees."

If they license practitioners at this pace, there could be quite a waiting line.